• Citer

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy

par Von Minckwitz, Gunter;Martin, Miguel;Wilson, Gregory G.J.;Alba, Emilio;Schmidt, Marcus;Biganzoli, Laura ;Awada, Ahmad
Référence Critical reviews in oncology/hematology, 85, 3, page (315-331)
Publication Publié, 2013-03

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

The first-generation taxanes, conventional paclitaxel and docetaxel, are established treatment options for adjuvant and metastatic breast cancer (MBC). However, these agents have limitations, including primary/secondary resistance and harsh toxicities. The introduction of paclitaxel albumin represents a significant advance in taxane therapy as the first of a new generation of taxanes. This agent utilizes albumin pathways to achieve enhanced and targeted drug delivery to the tumour. The lack of solvent also means that it is well tolerated, despite the lack of premedications. Paclitaxel albumin is licensed in the United States and Europe as ≥2nd-line therapy in MBC (260mg/m2 once every three weeks), but emerging evidence suggests it has activity in various settings as weekly therapy and in combination with other agents. Additional strategies to optimize taxane-based therapy are also being evaluated, including the possibility of tailoring treatment according to patient/disease characteristics, identifying predictive biomarkers and evaluating other novel taxanes. © 2012 Elsevier Ireland Ltd.